Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Don’t start with moon shots. by Thomas H. Davenport and Rajeev Ronanki In 2013, the MD Anderson Cancer Center launched a “moon shot” project: diagnose and recommend treatment plans for certain forms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results